Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + anlotinib + ET-SPACE hyperthermia
- Development stage
- Unknown
- Lead developer
- Pengyuan Liu
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This multimodal therapeutic regimen combines the immune checkpoint inhibitor tislelizumab, the multi-target receptor tyrosine kinase (RTK) inhibitor anlotinib, and ET-SPACE near-infrared whole-body hyperthermia. Tislelizumab is a humanized IgG4 monoclonal antibody that targets PD-1, preventing its interaction with PD-L1 and PD-L2 to restore anti-tumor immune responses. Anlotinib inhibits multiple RTKs, including VEGFR, FGFR, PDGFR, and c-Kit, exerting anti-angiogenic and anti-proliferative effects. The ET-SPACE device provides whole-body thermal stimulation (reaching rectal temperatures of 38.5–39 °C), which is intended to sensitize the tumor to the pharmacological agents and enhance the overall anti-tumor immune response. This combination is being evaluated in a Phase 2 study led by Pengyuan Liu for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
- Other names
- ET-SPACE Hyperthermia with Tislelizumab and Anlotinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on tislelizumab + anlotinib + ET-SPACE hyperthermia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + anlotinib + ET-SPACE hyperthermia.